Baker Bros. Advisors (RVMD) discloses 11.4M-share position in Revolution Medicines

BeOne Medicines AG (ONC) and Revolution Medicines, Inc. (RVMD) announced a multi-part clinical collaboration and licensing deal. BeOne will combine select BeOne assets with Revolution’s four RAS(ON) inhibitors and gain exclusive development and commercialization rights in parts of Asia (ex-Japan and South Korea), while Revolution keeps ex-Asia rights and may receive milestones and royalties. BeOne reported Q2 2026 revenue of $1.7B and $6.6–$6.8B full-year guidance; RVMD reported a Q2 2026 net lo

Revolution Medicines (NASDAQ:RVMD) announced a multi-part collaboration with BeOne Medicines on Aug. 10. The deal pairs RVMD’s RAS(-ON) inhibitors (daraxonrasib, zoldonrasib, elironrasib, RMC-5127) with BeOne assets in clinical studies and grants BeOne exclusive development and commercialization rights in select Asian markets, with milestone payments and royalties. RVMD cited daraxonrasib median overall survival of 13.2 months in April pancreatic cancer data.

Revolution Medicines (RVMD) shares rose 9.4% after reporting Q2 2026 results. Net loss widened to $644.37 million, or $3.06 loss per share, and first-half net loss totaled $1.10 billion. The company said the FDA accepted its daraxonrasib NDA for previously treated metastatic pancreatic cancer, with over 2,000 patients treated via compassionate use and $3.9 billion cash.

Revolution Medicines (RVMD) reported a wider-than-expected adjusted Q2 2026 loss of $2.34 per share versus a $1.93 consensus estimate. Including a $151 million non-cash warrant fair-value charge from its EQRx acquisition, the loss was $3.06 per share. The company raised 2026 operating expense guidance to $2.1-$2.2 billion and ended June with $3.9 billion cash.

Revolution Medicines, Inc. (RVMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 rvmd-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Revolution Medicines Reports Second Quarter 2026 Financial Results and Update on Corporate Progress · U.S. FDA accepted daraxonrasib New Drug Application for review for previously treated metastatic pancreatic cancer followin

Revolution Medicines (RVMD) shares rose about 5.3% after the U.S. FDA accepted its daraxonrasib NDA for priority review in previously treated metastatic pancreatic ductal adenocarcinoma. The filing is based on Phase 3 RASolute 302 results, and the drug has Breakthrough Therapy and Orphan Drug designations plus National Priority Voucher inclusion. The article cites $1.6b to $1.7b operating expense guidance and forecast $1.0b revenue by 2029.